Sol-Gel Technologies (SLGL) Debt Ratio (2016 - 2025)

Sol-Gel Technologies (SLGL) posted quarterly Debt Ratio of 0.03 for Q2 2025, down 99.19% quarter-over-quarter from 4.27 in Q4 2017.

Sol-Gel Technologies (SLGL) Debt Ratio (2016 - 2025) Analysis & Trends

Sol-Gel Technologies (SLGL) has reported Debt Ratio for 3 consecutive years, with 0.03 the latest figure, recorded in Q2 2025.

In Q2 2025, Debt Ratio changed N/A year-over-year to 0.03; the TTM figure through Jun 2025 stood at 0.03 (changed N/A YoY), while the FY2017 annual figure was 4.27, up 25.52% from the prior year.
Debt Ratio declined to 0.03 in Q2 2025 per SLGL's latest filing, from 4.27 in the prior quarter.
Across five years, Debt Ratio topped out at 0.03 in Q2 2025 and bottomed at 0.03 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Sol-Gel Technologies	240.26 Mn	230.12 Mn	-	-

Download Data